NCT06819566RecruitingPhase 2
Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC
Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma : A Phase II, Multicenter, Single-arm Trial (ESCOAT Trial)
Source: ClinicalTrials.gov · Last updated 24 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this study is to evaluate whether prophylactic endoscopic variceal ligation (EVL) can prevent esophageal variceal bleeding in patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev) therapy. The study will also assess the safety of prophylactic EVL in this population. The main question it aims to answer is: Does prophylactic EVL in high-risk varices reduce the incidence of variceal bleeding to a level similar to that of low-risk varices in HCC patients receiving Atezo/Bev? Participants will: 1. Undergo prophylactic EVL before starting Atezo/Bev therapy (within 2 weeks ± 1 week before the first dose). 2. Start Atezo/Bev therapy 2 weeks (± 1 week) after EVL. 3. Have follow-up endoscopies (EGD) one week after the 3rd, 5th, and 7th doses of Atezo/Bev. If varices improve, no additional intervention is needed. If varices persist or worsen, on-demand EVL will be performed, and Atezo/Bev will continue. This study will help determine if prophylactic EVL should be a standard strategy for managing high-risk varices in HCC patients undergoing Atezo/Bev therapy.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 31 Dec 2024
- Start date
- 28 May 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Asan Medical Center
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06819566
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 44
- From 28 May 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who have previously received systemic anticancer therapy for advanced hepatocellular carcinoma.
- Patients with a prior history of liver transplantation.
- Previous Variceal Treatments: Patients who have undergone any of the following treatments for variceal bleeding:
- Endoscopic Variceal Obliteration (EVO) B. EVL C. Transjugular Intrahepatic Portosystemic Shunt (TIPS) D. Percutaneous Approach for Retrograde Transvenous Obliteration (PARTO) E. Surgical procedures
- Patients who have used anticoagulants or antiplatelet agents within one week prior to the study.
Other illness
- with uncontrolled malignant tumors other than HCC at the time of enrollment (participation is allowed if disease-free survival exceeds two years).
- Patients with uncontrolled or serious underlying diseases requiring treatment.
- Patients with a history of esophageal or gastric variceal bleeding.
Other
- Patients with intrahepatic tumor involvement of 50% or more.
- Patients with tumor thrombus in the main portal vein or both first-order branches (Vp4).
- Presence of grade 2 or higher isolated gastric varices or Red Color Signs confirmed by baseline endoscopy (EGD).
- Patients who are pregnant.
- Patients who are unable to understand or provide written informed consent.
- Patients deemed unsuitable for clinical study participation based on the investigator's judgment.
Who the study is looking for
- Patients aged 19 years or older and under 80 years.
- Patients with liver function are classified as Child-Pugh Class A.
- Barcelona Clinic Liver Cancer stage C patients with no prior systemic anticancer therapy for hepatocellular carcinoma.
- Patients with an Eastern Cooperative Oncology Group performance score of 0-1.
- Adequate Hematologic and Liver Function:
- Hemoglobin: ≥ 9.0 g/dL B. Absolute Neutrophil Count : ≥ 1,000/mm³ C. Platelet Count: ≥ 70,000/μL D. Prothrombin Time: ≥ 70% (or Prothrombin Time INR ≤ 1.2)
- Patients with upper gastrointestinal endoscopy performed within six months prior to the start of anticancer treatment.
- No plans for breastfeeding, and if of childbearing potential, using contraception or no plans for spouse's pregnancy or practicing contraception.
- Patients who have received an explanation of the treatment purpose and methods and have provided informed consent for the treatment.
Age in the registry: 19 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Liver cancer center, Asan Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.